Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, describes updates in the field of mesothelioma. Immunotherapy for patients who progress from chemotherapy have demonstrated mixed results, with the PROMISE-meso trial (NCT02991482) showing pembrolizumab to not be as efficacious as standard chemotherapy. However, nivolumab plus ipilimumab resulted in superior survival in the CONFIRM (NCT03063450) and CheckMate 743 (NCT02899299) trials. Prof. Popat additionally recommends immunotherapy in non-epithelioid mesothelioma in the first line setting. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.